User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 148.50 145.00 152.00 149.50 148.50 149.50 52,672 12:10:40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 84

Reneuron Share Discussion Threads

Showing 8126 to 8147 of 8300 messages
Chat Pages: 332  331  330  329  328  327  326  325  324  323  322  321  Older
DateSubjectAuthorDiscuss
12/1/2021
17:02
Another great day. It's looking exciting.
small crow
12/1/2021
14:10
Real momentum building, could easily mirror what happened in April/May 2019.
katsy
12/1/2021
10:39
Worth sharing the link in that TS! Https://www.proactiveinvestors.co.uk/companies/news/928730/reneuron-group-says-dosing-has-begun-on-expanded-phase-iia-trial-of-eye-disease-treatment-928730.html This is good to read: The hRPC update was part of a broader trading statement delivered ahead of ReNeuron’s annual meeting in which it reiterated its belief it will see increasing industry interest in its exosomes programme translate into further collaborations. It has already signed two research evaluation agreements with companies interested in exploring the potential of the technology. “In addition, we expect to be able to sign further collaboration agreements, currently under negotiation, in the near term,” the company added. Let's hope the expectations translate to facts! PS. Note the article is from Sept 2020, but still worth repeating. Must be getting nearer!
lauders
12/1/2021
10:26
Brilliant must read thread on #RENE this RENE now potentially a world leading company in a whole new biotechnology platform technology area Exosomes (Recent Goldman Sachs IPO CDAK Codiak went from $150m to $600m) RENE EV of £40m doesn't do justice to the potential for positive newsflow on this exciting prospect No wonder Professor Sir Chris Evans invested £1m in recent fundraising htTps://twitter.com/hareng_rouge/status/1348748130427285504?s=20
the stigologist
12/1/2021
09:09
Breaking out
the stigologist
08/1/2021
09:50
I dare say that someone who co-founded and then sold an $800M company is not exactly living paycheck to paycheck. He may well have invested although I imagine there would be complications regarding potential insider information so this would need to be handled carefully.
whatno
08/1/2021
08:24
Is this traded on multiple exchanges?
katsy
07/1/2021
15:49
Why would further collaborations be a huge catalyst? The previous 3 werent. I think you may have to wait for the end of the proof of concepts and subsequent licence agreements
luffness
07/1/2021
15:37
He may have built it but the sale might involve large contingent back ended payouts so who knows how much he has to invest Prof Evans put £1m in
the stigologist
07/1/2021
15:34
if that was the case then bg3 he will buy a big chunk ??
martinfrench
07/1/2021
14:34
I've been a holder here for a while, just listened to the analyst call. Lots of little snippets a non-scientist such as myself can take away. Re prof Maclaren, built and sold Nightstar for $830m, saw the results here and asked to be involved. He wouldn't be doing that if he didn't see something to get excited about !
bg23
07/1/2021
14:15
It's clear from the call that Prof Maclaren is going to be guiding the RP clinical trial going forwards. He has already shaped it by proposing further endpoints that RENE have now included. These will significantly improve the chances of approval by the FDA. Let's not forget that he was the driver behind Nightstar that was sold for $800M.and that a single shot of Luxturna has been approved by NICE @£600k!
onceaday
07/1/2021
13:57
That slide on Value Inflection Points makes it pretty clear we should expect Pharma collabs like err imminently... January 2021 right ? Which is going to be a huge catalyst if they pull it off Next week's Biotech Showcase and JPM Healthcare Conference perfect time to deliver news as well htTps://twitter.com/Stockonomist/status/1347182124311470081?s=20
the stigologist
07/1/2021
09:22
htTps://twitter.com/JMHDeakin/status/1346955581114953728?s=20
the stigologist
07/1/2021
09:21
Nice stealth breakout of medium term downtrend going on
the stigologist
06/1/2021
15:48
All quite positive. They really need to ensure they meet the target of all 9 RP patients treated by early Q2. They have had plenty of time to prepare for the trial. Exosomes have real potential for near term value creation. They are working with 3 third party therapeutics and I was pleased.to hear they have another two in the pipeline and are only constrained by RENE's resources. If just a few of these bear fruit the value coming through could be huge.
onceaday
06/1/2021
15:34
Just finished listening to this morning's presentation. Worth a listen. hTTps://webcasting.buchanan.uk.com/broadcast/5fd23c59ca22cd76f9d3c662/5ff5a61365d56b44935101d1
pdt
06/1/2021
10:47
Well, someone’s taking a optimistic view!
rayrac
06/1/2021
10:36
I doubt they will reveal material non public info The idea of these is to present long term themes and help Analysts understand the drivers and catalysts so they can explain it to the buy side IIs
the stigologist
06/1/2021
10:35
Great start.
small crow
06/1/2021
10:28
Meeting results?
rayrac
05/1/2021
17:11
Great finish
the stigologist
Chat Pages: 332  331  330  329  328  327  326  325  324  323  322  321  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210507 14:19:15